Korea Reimbursement (HIRA/NECA): The Path After Market Authorization

Approval Is Not Access

Foreign manufacturers consistently treat MFDS approval as the finish line for Korea entry. It is not. Approval grants the right to import and sell, but Korea's single-payer national health insurance system — administered by the National Health Insurance Service (NHIS) — determines whether the device is reimbursable under the public coverage scheme. For most non-trivial devices, hospital adoption follows reimbursement, not approval. A device that is approved but not reimbursed is, in practical commercial terms, a niche or self-pay product.

The Korean reimbursement system has two relevant institutions and two distinct review processes:

• HIRA (Health Insurance Review and Assessment Service) — sets coverage codes, billing rules, and price points for routine reimbursement under NHIS.
• NECA (National Evidence-based Healthcare Collaborating Agency) — performs new health technology assessment (nHTA) for genuinely novel technologies that fall outside existing HIRA categories.

The path through these two depends on whether your device fits an existing reimbursement category.

The Three Reimbursement Outcomes

When a newly approved device enters the Korean market, it lands in one of three states:

1. Routine (Existing Category)

The device fits cleanly into an existing HIRA reimbursement code. The price is the established code price; the manufacturer files for the device to be added to the code's product list. Timeline: 2–4 months. Most consumable accessories and incremental device updates follow this path.

2. New Code (Innovation Within Category)

The device is recognizably similar to existing reimbursed products but improves on them — higher accuracy, lower complication rate, faster procedure time. The manufacturer files an upper price band application or a new sub-code request. HIRA reviews clinical and economic evidence. Timeline: 6–12 months. Approval rate varies sharply by therapeutic area.

3. nHTA (Genuinely Novel)

The device represents a new health technology — typically novel AI/SaMD, novel implant, novel diagnostic modality — without an existing reimbursement category. The manufacturer files with NECA for new technology assessment. NECA's review can result in:

• Reimbursed (rare, ~10–15% of first-pass nHTA applications)
• Limited use (covered under conditions: specific indications, specific hospitals, or sample-restricted)
• Conditional approval pending evidence (provisional 2–3 year reimbursement with evidence collection requirements)
• Non-reimbursed (approved for sale but billed at hospital discretion)

Timeline: 12–24 months. This is the highest-leverage and highest-risk path.

Evidence Expectations Differ from FDA/EU

The Korean reimbursement reviewer is not the regulator. The questions asked are economic and clinical-comparative, not safety-and-performance.

Dimension	MFDS approval	HIRA/NECA reimbursement
Primary question	Is it safe and effective?	Does it provide value over alternatives?
Comparator	Predicate or equivalent product	Standard of care in Korea
Evidence base	Performance data, biocompatibility, cybersecurity	Cost-effectiveness, outcomes vs Korean SoC
Patient data origin	Can be international with validation	Strongly prefers Korean patient data
Decision driver	Regulatory risk	Budget impact + clinical incremental value

A device that breezes through MFDS can stall at HIRA because the cost-effectiveness model uses Korean Standard-of-Care comparators with which the manufacturer has no familiarity.

What to File: The Five-Part Reimbursement Dossier

For HIRA new-code or nHTA applications:

1. Clinical evidence package — published evidence, prioritizing studies with Korean patient cohorts or East Asian populations.
2. Health economic model — cost per QALY or budget impact, anchored on Korean tariffs and Korean clinical practice patterns. International economic models do not transfer.
3. Comparator analysis — head-to-head against the Korean standard-of-care, not against the global SoC.
4. Hospital adoption plan — typically demonstrated through letters of interest from Korean academic medical centers.
5. Pricing proposal — anchored to international reference pricing (the IRP basket) but adjusted for Korean market conditions.

Pricing: The IRP Constraint

Korea uses an International Reference Pricing (IRP) basket of typically seven countries (varies by product type) as a price ceiling reference. The Korean price is generally set at or below the lowest reference country's price. Manufacturers with EU launch pricing should model that Korea will land 10–25% below EU price points, and that any subsequent EU price reduction will pull Korean price down by IRP mechanism.

This makes Korea launch sequencing important. Launching Korea before high-revenue EU markets gives less negotiating leverage; launching after locks in IRP ceilings that may not be commercially viable.

Three Common Failure Modes

Failure 1: Treating reimbursement as a post-approval afterthought. Reimbursement work should start at the MFDS submission stage, not after approval. The Korean clinical validation data you collect for MFDS can — with the right design — also serve HIRA. Splitting these workstreams duplicates clinical work.

Failure 2: Using a global economic model. A €60K-per-QALY cost-effectiveness analysis from NICE does not transfer to Korea. The HIRA threshold, the comparator costs, the lifetime modeling assumptions — all need Korean inputs. Use the global model as a structure, not as a deliverable.

Failure 3: No Korean KOL pre-engagement. HIRA and NECA both informally consult with Korean clinical KOLs in the relevant specialty. A product with no Korean KOL relationships at submission time is a product with no informal advocates. KOL engagement should begin during clinical validation, not at reimbursement submission.

nHTA: When to Choose This Path Deliberately

Manufacturers with truly novel products sometimes ask whether to avoid nHTA — to position the product within an existing HIRA code rather than seek a new technology assessment. The trade-off:

• Within existing code: faster reimbursement, lower price ceiling, lower differentiation in physician adoption decisions.
• nHTA path: longer review, potential premium pricing if approved, stronger differentiation as a "new technology."

For high-value implants, novel SaMD, and genuinely first-in-Korea technologies, the nHTA path generally produces better commercial outcomes despite the longer timeline. For incremental improvements, fitting within existing codes is usually faster and commercially adequate.

Conditional Approval: Underused Lever

NECA's conditional approval pathway — provisional 2–3 year reimbursement with evidence collection — is underused by foreign manufacturers because it requires committing to Korean real-world evidence (RWE) collection over the conditional period. For products with limited Korean clinical data at launch, this is often the most pragmatic path: it secures reimbursement, locks in revenue, and produces the Korean data that supports permanent reimbursement at year 3.

Where Leanabl Plugs In

Our Korea Reimbursement solution carries HIRA and NECA workstreams, including economic modeling with Korean cost inputs and Korean KOL engagement. For manufacturers running the full path from approval through reimbursement, Korea Full Market Authorization bundles MFDS, KGMP, and reimbursement into one program. The Korea Portfolio MA variant extends this to multi-product reimbursement strategy.